期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗联合培美曲塞加顺铂一线治疗Ⅳ期非小细胞肺癌的临床观察 被引量：47

暂未订购
导出
摘要 目的观察贝伐单抗联合培美曲塞加顺铂一线治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及不良反应。方法回顾性分析我院2009年～2012年经病理学确诊的Ⅳ期腺型NSCLC病例47例,其中22例采用贝伐单抗联合培美曲塞加顺铂方案治疗(研究组),25例采用培美曲塞加顺铂方案治疗(对照组),观察其疗效和不良反应,并进行随访。结果研究组与对照组的客观有效率分别为63.3%和32.0%(P<0.05),疾病控制率分别为86.3%和72.0%(P>0.05),中位无进展生存期分别为8.5月、6.2月(P<0.05),中位生存期分别为15.0月、11.9月(P<0.05)。研究组较对照组增加的不良反应主要有高血压、出血,发生率分别为27.2%、13.6%,但均为Ⅰ～Ⅱ级,经药物治疗后均可控制,不影响化疗的连续性。结论贝伐单抗联合培美曲塞加顺铂一线治疗晚期腺型NSCLC能够使疗效提高,生存时间延长,且患者耐受性较好,具有很好的临床应用前景。
作者 杨晓利 王峰 何炜 樊青霞
机构地区 郑州大学第一附属医院肿瘤科
出处 《西安交通大学学报（医学版）》 CAS CSCD 北大核心 2013年第4期554-556,共3页 Journal of Xi’an Jiaotong University（Medical Sciences）
关键词 非小细胞肺癌 贝伐单抗 培美曲塞 顺铂 化疗 不良反应
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1D'ADDARIO G, FRUH M, RECK M, et al. Metastatic nonsmall-cell lung cancer, ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oneal, 2010, 21 (S): 116-119.
  • 2BALDWIN CM, PERRY CM. Pemetrexed , a review of its use in the management of advanced non-squamous non-small cell lung cancer [J]. Drugs. 2009, 69(16): 2279-2302.
  • 3JARDIM DLF. GAALIATO DDM. RIBEIRO KB. et al. Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: A Brazilian center experience [J]. Drugs RD. 2012, 12(14) :207-216.
  • 4CRIN6 L. DANSIN E. GARRIDO P. et al. Safety and efficacy of first-line bevacizurnab-based therapy in advanced nonsquamous non-small-cell lung cancer (SAiL, MOI9390): a phase 4 study [J]. Lancet Oncol , 2010, 11(8) :733-740.
  • 5SCAGLIOTI G, PARIKH p, VON PAWEL J, et al. Phase 1lI study comparing cisplatin plus gemcitabion with cisplatin plus pernetrexed in chemotherapy: native patients with advancedstage non-small cell lung cancer [J]. J Clin Oncol , 2008, 26 (21) ,3543-3551.
  • 6WAQSTAFF AJ, KEAM SJ, MCCORMACK PL. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer [J]. Bio Drugs, 2009, 23(3):187-196.
  • 7TENG LS, JIN KT, HE KF, et al. Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment [J]. J Chin Med Assoc , 2010, 73 (6) ,281-288.
  • 8VAZIRI SA, KIM J, GANAPATHI MK. et al. Vascular endothelial growth factor polymorphisms. role in response and toxicity of tyrosine kinase inhibitors [J]. CUrT Oneol Rep, 2010, 12(2),102-108.
  • 9CHOWDURY MW, SCARAMUZZI RJ, WHEELER-JONES Cp, et al. The expression of angiogenic growth factors and their receptors in ovarian follicles throughout the estrous cycle in the ewe [J]. Theriogenology , 2010,73(7) :856-872.
  • 10RECK M, PAWELJV, ZATLOUKAL P, et al. Phase ill trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL [J]. J Clin Oncol , 2009, 27(4):1227-1234.

二级参考文献9

  • 1梅同华,徐小杰.TP与NP方案治疗晚期非小细胞肺癌的疗效比较[J].中国药房,2005,16(2):127-128. 被引量：15
  • 2Manegold C,Pawel J von,Zatloukal P,et al.Ran-domised,double-blind multicenter phaseⅢstudy of bev-acizumab in combination with cisplatin and gemcitabine inno nc-hseqmuaomthoeurasp nyo-nna-s?vmea plla tcieelnl tslu wngit hc aandcvear (ncNedS-oCr LreCc)u:rrBenOt17704. Journal of Clinical Oncology . 2007
  • 3Ferrara N.Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews . 2004
  • 4Herbst R,O‘Neill V,Fehrenbacher L,et al.A phase Ⅱ,multicenter,randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or. Journal of Clinical Oncology . 2006
  • 5Ferrara N.Vascular endothelial growth factor as a target for anticancer therapy. The Oncologist . 2004
  • 6Mohammed KA,Nasreen N,Hardwick J,et al.Bacterial induction of pleural mesothelial monolayer barrier dysfunction. American Journal of Physiology Lung Cellular and Molecular Physiology . 2001
  • 7FERRARA N,HILLAN K J,NOVOTNY W.Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications . 2005
  • 8P Therasse,SG Arbuck,EA Eisenhauer,et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute . 2000
  • 9Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, The . 2006

共引文献10

同被引文献355

引证文献47

二级引证文献309

西安交通大学学报（医学版）
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部